MedDRA preferred term

Blood creatine phosphokinase increased: adverse event reports recording this term

28,555 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

28,555
reports recording the term: 0.1% of all reports; 790
reports, 12 months to June 2026: 1,215 in the 12 months before; 89.5%
marked serious by the reporter: 57.4% across all reports; 5.9%
record death among outcomes, as reported: 9.1% across all reports

28,555 reports in FDA's adverse event database record the MedDRA term "Blood creatine phosphokinase increased": 0.1% of all reports received between January 2004 and March 2026. Coders pick the term that best matches the reporter's description.

790 reports recorded it in the 12 months to June 2026, down 35% from 1,215 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 89.5% are marked serious, 5.9% include death among the outcomes and 50% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Simvastatin, Lipitor and Atorvastatin. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Simvastatin	HMG-CoA reductase inhibitor	1,531	4.3%
Lipitor	HMG-CoA reductase inhibitor	1,132	2.1%
Atorvastatin	—	1,042	2.3%
Crestor	HMG-CoA reductase inhibitor	997	2.3%
Rosuvastatin	HMG-CoA reductase inhibitor	587	2.9%
Olanzapine	Atypical antipsychotic	584	1.2%
Zocor	HMG-CoA reductase inhibitor	569	5.5%
Clozaril	Atypical antipsychotic	559	1.2%
Cubicin	—	502	7.9%
Quetiapine	Atypical antipsychotic	485	0.9%
Clozapine	Atypical antipsychotic	445	0.6%
Abilify	Atypical antipsychotic	442	0.8%
Atorvastatin calcium	HMG-CoA reductase inhibitor	439	2.2%
Risperidone	Atypical antipsychotic	423	0.9%
Zetia	Dietary cholesterol absorption inhibitor	366	4.4%
Aripiprazole	Atypical antipsychotic	359	1.2%
Daptomycin	—	327	4.8%
Haloperidol	Typical antipsychotic	306	2.1%
Repatha	PCSK9 inhibitor	301	0.2%
Zyprexa	Atypical antipsychotic	295	1.1%
Ezetimibe	Dietary cholesterol absorption inhibitor	293	2.6%
Propofol	General anesthetic	253	1.3%
Sertraline	Serotonin reuptake inhibitor	253	0.6%
Risperdal	Atypical antipsychotic	250	0.5%
Levetiracetam	—	243	0.5%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
HMG-CoA reductase inhibitor	5,800	2.8%	2.9%
Atypical antipsychotic	4,608	0.7%	0.4%
Kinase inhibitor	1,981	0.2%	0.1%
Serotonin reuptake inhibitor	1,187	0.4%	0.4%
Benzodiazepine	1,080	0.4%	0.5%
Anti-epileptic agent	882	0.3%	0.2%
Dietary cholesterol absorption inhibitor	843	3.6%	4.4%
Programmed death Receptor-1 blocking antibody	671	0.3%	0.3%
Nonsteroidal anti-inflammatory drug	662	0.1%	0%
Opioid agonist	598	0.1%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.7%200

2 to 111.4%397

12 to 172.4%699

18 to 4419.2%5,478

45 to 6426.1%7,459

65 to 7414.3%4,086

75 and over11.7%3,337

Age not given24.2%6,899

Patient sex

Female34.8%9,944

Male56.1%16,019

Not given9.1%2,592

Grey bar: all 20,646,523 reports in the database. 26.3% of these reports give the United States as the country.

Questions about "Blood creatine phosphokinase increased"

What does "Blood creatine phosphokinase increased" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record blood creatine phosphokinase increased?

28,555 reports through June 2026 (0.1% of all reports), 790 of them in the latest 12 months.

Which drugs appear most often in these reports?

Simvastatin (1,531), Lipitor (1,132), Atorvastatin (1,042), Crestor (997) and Rosuvastatin (587). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.